Golden Biotechnology Corp.

DUBLIN--( BUSINESS WIRE )--The "MEK Inhibitors - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for MEK Inhibitors is estimated at US$995.1 Million in 2023 and is projected to reach US$1.5 Billion by 2030, growing at a CAGR of 5.9% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The growth in the MEK inhibitors market is driven by several factors, including the rising prevalence of cancers that are susceptible to these treatments and the ongoing discoveries in cancer genomics that offer insights into new therapeutic targets. The expansion of clinical trials to explore different combinations and sequences of MEK inhibitors with other cancer therapies is also a critical factor, pushing the boundaries of current cancer treatment paradigms. Furthermore, advancements in diagnostic technologies that allow for quicker and more accurate identification of mutations in cancer cells facilitate the appropriate selection of patients who are likely to benefit from MEK inhibitor therapies. Consumer behavior, particularly the increasing demand for more personalized and less invasive treatment options, further fuels the adoption of targeted therapies like MEK inhibitors. Lastly, regulatory incentives for the development of orphan drugs and fast-track approval processes in many countries encourage pharmaceutical companies to invest in the research and development of these drugs, ensuring a robust pipeline of new MEK inhibitors entering the market. This combination of scientific advancement, clinical need, regulatory support, and market demand ensures continued growth and innovation within the MEK inhibitors market, promising improved outcomes for cancer patients around the world. Regional Analysis: Gain insights into the U.S. market, estimated at $271.1 Million in 2023, and China, forecasted to grow at an impressive 9.6% CAGR to reach $316.8 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of major players such as AstraZeneca plc, Boehringer Ingelheim International GmbH, Day One Biopharmaceuticals, Inc., and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Key Attributes: Report Attribute Details No. of Pages 132 Forecast Period 2023 - 2030 Estimated Market Value (USD) in 2023 $995.1 Million Forecasted Market Value (USD) by 2030 $1500 Million Compound Annual Growth Rate 5.9% Regions Covered Global Key Topics Covered: MARKET OVERVIEW Influencer Market Insights World Market Trajectories Global Economic Update MEK Inhibitors - Global Key Competitors Percentage Market Share in 2024 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E) MARKET TRENDS & DRIVERS Understanding the Value of MEK Inhibitors in Cancer & Cancer Therapy Increased Incidence of Melanoma and Other Cancers Propel Demand Integration of MEK Inhibitors in Combination Cancer Therapy Protocols Expansion of Treatment Indications Beyond Oncology Market Entry of Generic and Biosimilar Therapeutic Options Ethical and Regulatory Issues in Cancer Drug Trials FOCUS ON SELECT PLAYERS (Total 36 Featured) AstraZeneca plc Boehringer Ingelheim International GmbH Day One Biopharmaceuticals, Inc. Genentech, Inc Golden Biotechnology Corporation Immuneering Corportion Merck KGaA (MilliporeSigma) Novartis International AG Ono Pharmaceutical Co., Ltd. Pfizer, Inc. Pierre Fabre S.A. Shanghai Fosun Pharmaceutical (Group) Co., Ltd SpringWorks Therapeutics Inc Suzhou Zelgen Biopharmaceuticals Co., Ltd Verastem, Inc. For more information about this report visit https://www.researchandmarkets.com/r/vsowi8 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

▎药明康德内容团队编辑今日，国鼎生技（Golden Biotechnology）于美国临床肿瘤学会（ASCO）胃肠道肿瘤研讨会中公布其药品Hocena（antroquinonol）用于一线治疗转移性胰腺癌的2期临床试验积极结果。分析显示，当antroquinonol联合标准治疗方案时，患者的中位总生存期（OS）达14.1个月，显著高于标准疗法在过去3期试验中所达到的8.5个月。该研究显示，接受antroquinonol联合标准治疗的受试者出现具有临床意义的缓解。与标准治疗（白蛋白结合型紫杉醇+吉西他滨）3期试验结果相比，该治疗在6个月和12个月时均展现显著更长的总生存期和总生存率。接受antroquinonol联合标准方案、标准方案、吉西他滨单药患者的总生存期分别为14.1、8.5和6.7个月。6个月时相应的总生存率分别为85.5%、67%和55%，而12个月时的总生存率则分别为62.2%、35%和22%。此外，接受antroquinonol联合标准方案患者的总生存期亦显著高于接受另一种化疗方案FOLFIRINOX的患者。Antroquinonol联合疗法组患者的总生存期、6个月与12个月的总生存率分别为14.1个月、85.5%与62.2%。FOLFIRINOX组患者则为11.1个月、76%与48%。此外，antroquinonol联合标准治疗药物的中位无进展生存期（PFS）为5.3个月，6个月的无进展生存率为41.7%。值得一提的是，美国临床肿瘤学会委员会为胰腺癌、乳腺癌、肺癌和结直肠癌的临床试验定义了具有临床意义的目标。对于适合接受吉西他滨或吉西他滨/白蛋白结合型紫杉醇治疗的胰腺癌患者，当前基线中位总生存期估计范围为8-9个月。如果与当前总生存期相比的最小改善在3-4个月之间，则被认为“具有临床意义”。Antroquinonol是一种具有多种功能的新化学实体（NCE），通过抑制蛋白质异戊烯基转移酶活性，抑制RAS及其相关的GTP结合蛋白激活，从而激活癌细胞中的自噬作用与相关的细胞死亡。超过30%的所有人类癌症，包括95%的胰腺癌，是由RAS家族突变所驱动。Antroquinonol还作用于PI3K/AKt/mTOR通路，影响癌细胞的自噬和凋亡。它具有在不损害正常细胞的情况下靶向癌细胞的能力，因此可能改善药物的耐受性，并同时提高安全性。此外，它可以口服，为患者提供方便的治疗选择。美国FDA已授予其治疗胰腺癌、急性髓系白血病（AML）和肝细胞癌的孤儿药资格（ODD），欧洲药品管理局（EMA）也授予其治疗胰腺癌的ODD。大家都在看药明康德为全球生物医药行业提供一体化、端到端的新药研发和生产服务，服务范围涵盖化学药研发和生产、生物学研究、临床前测试和临床试验研发、细胞及基因疗法研发、测试和生产等领域。如您有相关业务需求，欢迎点击下方图片填写具体信息。▲如您有任何业务需求，请长按扫描上方二维码，或点击文末“阅读原文/Read more”，即可访问业务对接平台，填写业务需求信息▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料：[1] ASCO GI 2024: Golden Biotech's Antroquinonol Shows Significantly Prolonged Survival in Untreated Metastatic Pancreatic Cancer Patients. Retrieved January 18, 2024 from https://www.prnewswire.com/news-releases/asco-gi-2024-golden-biotechs-antroquinonol-shows-significantly-prolonged-survival-in-untreated-metastatic-pancreatic-cancer-patients-302038201.html免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

Pancreatic cancer. Golden Biotechnology has shared updated data on its mushroom-derived drug candidate in metastatic pancreatic cancer, linking first-line use of the molecule to median overall survival (OS) of 14.1 months. People with metastatic pancreatic cancer lack good options, to the extent that the National Institutes of Health recommends that all newly diagnosed patients should consider enrolling in clinical trials. Chemotherapy remains the least bad option for many patients, with the FOLFIRINOX cocktail and gemcitabine-nab-paclitaxel combination respectively chalking up median OS figures of 11.1 months and 8.5 months. Another chemotherapy regimen, NALIRIFOX, also achieved a median OS of 11.1 months last year. Golden Biotech is presenting data on its attempt to clear that OS bar at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium this week. The median OS in metastatic pancreatic cancer patients who received its drug antroquinonol, along with gemcitabine and nab-paclitaxel as a first-line treatment was 14.1 months. Median progression-free survival clocked in at 5.3 months. The OS has increased since an earlier look at the data, when it came in at 12.6 months. In 2014, an ASCO committee said a 4-5 month improvement over FOLFIRINOX, or 3-4 month edge over gemcitabine-nab-paclitaxel, would be clinically meaningful. Research suggests more patients are eligible for gemcitabine-nab-paclitaxel than the more effective FOLFIRINOX.  In the absence of a control arm, it is impossible to tell whether adding antroquinonol to the treatment mix improves on the OS achieved by chemotherapy. Investors appeared unmoved, with little change in the Taiwanese biotech’s share price on the Taipei Exchange. Golden Biotech’s statement lacks a close look at the safety and tolerability results. An earlier cut of the data showed the rates of neutropenia, thrombocytopenia and anemia were lower in the antroquinonol group than in an earlier chemotherapy trial, although the rates of vomiting and diarrhea were higher.  Antroquinonol is a ubiquinone derivative found in a mushroom that grows on a tree of Taiwan. Evidence that the molecule blocks RAS signaling has spurred Golden Biotech to advance the molecule in pancreatic cancer. Other biotechs are going after the cancer by targeting KRAS, NTRK fusions, RET and other drivers of pancreatic tumors.